Johnson & Johnson (JNJ) Tops Q2 EPS by 12c; Boosts FY14 EPS Outlook
(Updated - July 15, 2014 7:48 AM EDT)
Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $1.66, $0.12 better than the analyst estimate of $1.54. Revenue for the quarter came in at $19.5 billion versus the consensus estimate of $18.86 billion.
The Company increased its earnings guidance for full-year 2014 to $5.85 - $5.92 per share. The Street sees EPS of $5.90.
"Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, Chairman and Chief Executive Officer. "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."
Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 2.4% versus the prior year consisting of an operational increase of 3.6% and a negative impact from currency of 1.2%.
Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.
Positive contributors to operational results were sales of TYLENOL® and MOTRIN® analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids; NEUTROGENA® and AVEENO® skin care products; baby care products; and international sales of LISTERINE® mouthwash and feminine protection products.
Worldwide Pharmaceutical sales of $8.5 billion for the second quarter represented an increase of 21.1% versus the prior year on a total and operational basis. Domestic sales increased 36.6%. International sales increased 6.8% which reflected an operational increase of 6.9% and a negative currency impact of 0.1%.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.